SimpleTest by iAssay

The U.S. Response to the Novel Coronavirus Reflects the Potential of iAssay

founder @ SimpleTest by iAssay

Published on Jan 26, 2021

Just a year ago, the CDC followed by the private sector rushed to develop a test for novel Coronavirus with an initial goal to distinguish and detect COVID-19. Initially COVID testing was limited with turn around results of several days. The next goal was to improve testing turnaround times coupled with population studies for at risk or symptomatic individuals. COVID testing rapidly evolved with many new tests and new methodologies for both rapid testing and high-volume testing.

Recently, to re-open portions of the economy, COVID testing moved from collections of at-risk or symptomatic individuals to the testing of asymptomatic individuals (e.g., schools and airports).

SimpleTest™ by iAssay mirrors the goals of our Public Health system in response to the novel Coronavirus. Generally, by enabling the performing of tests in non-traditional laboratory sites (e.g., home), SimpleTest™ provides a path to early intervention, avoids referrals to the ER or hospital, and reduces health care dollars spends, helping to enable Value Based Care. One common use case is managing chronic diseases. Between 50% to 60% of adults suffer from one or more of the top five chronic diseases: Diabetes, hypertension, cardiac disease, depression, and asthma. These conditions account for 80% of America's $3.5 trillion in annual health care expenses. In allowing patients to monitor their symptoms without going to a lab, and with the unique ability to securely send test results to The Cloud where doctors can identify fluctuations in minutes instead of days, SimpleTest™ is poised to change diagnostic-driven medical care for the better.

See https://healthcaretransformers.com/digital-health/data-driven-value-based-care/for an interesting article on how SimpleTest™ can be an enabler for Value Based Care.